Cargando…
Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
Immune checkpoint inhibitor combination therapy exhibited outstanding efficacy in first line setting for advanced non-small cell lung cancer (aNSCLC) patients. However, whether PD-1 inhibitor combined treatment is effective in second line or later setting remains unknown. Therefore, we retrospective...
Autores principales: | Zhang, Fan, Huang, Di, Li, Tao, Zhang, Sujie, Wang, Jinliang, Zhang, Yuzi, Wang, Guoqiang, Zhao, Zhengyi, Ma, Junxun, Wang, Lijie, Sun, Danyang, Cui, Pengfei, Cai, Shangli, Jiao, Shunchang, Zhao, Lei, Hu, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959040/ https://www.ncbi.nlm.nih.gov/pubmed/31942197 http://dx.doi.org/10.7150/jca.37966 |
Ejemplares similares
-
Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for
patients with non-small cell lung cancer who have progressed after
platinum-based chemotherapy
por: Zhang, Fan, et al.
Publicado: (2020) -
Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort
por: Sun, Danyang, et al.
Publicado: (2018) -
Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study
por: Cui, Pengfei, et al.
Publicado: (2018) -
First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials
por: Zhai, Jinzhao, et al.
Publicado: (2022) -
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)